{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:34:28Z","timestamp":1793072068330,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.atherosclerosis.2025.120563","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:53:54Z","timestamp":1762671234000},"page":"120563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Lipid lowering therapies in chronic kidney disease: A call to action"],"prefix":"10.1016","volume":"411","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6548-0805","authenticated-orcid":false,"given":"Jaime","family":"Maz\u00f3n-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"de Cos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Riestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"S\u00e1nchez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gonz\u00e1lez Bores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nefro.2018.09.002","article-title":"The Spanish society of nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem","volume":"39","author":"Ortiz","year":"2019","journal-title":"Nefrologia"},{"issue":"10159","key":"10.1016\/j.atherosclerosis.2025.120563_bib2","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","article-title":"Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories","volume":"392","author":"Foreman","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1681\/ASN.2015050542","article-title":"CKD prevalence varies across the European general population","volume":"27","author":"Br\u00fcck","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12944-023-01833-z","article-title":"International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?","volume":"22","author":"Calice-Silva","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"1\u20133","key":"10.1016\/j.atherosclerosis.2025.120563_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000441737","article-title":"A review of pediatric chronic kidney disease","volume":"41","author":"Kaspar","year":"2016","journal-title":"Blood Purif"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib8","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","article-title":"Chronic kidney disease and mortality risk","volume":"17","author":"Tonelli","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"9889","key":"10.1016\/j.atherosclerosis.2025.120563_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfu038","article-title":"Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study","volume":"29","author":"Betriu","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.01240215","article-title":"Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD","volume":"11","author":"Gracia","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"issue":"9931","key":"10.1016\/j.atherosclerosis.2025.120563_bib13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120563_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"9731","key":"10.1016\/j.atherosclerosis.2025.120563_bib15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2025.120563_bib16","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin\u2013Angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120563_bib17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120563_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120563_bib19","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/ckj\/sfab113","article-title":"Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients","volume":"14","author":"Bermudez-Lopez","year":"2021","journal-title":"Clin Kidney J [Internet]"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2025.120563_bib20","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","article-title":"Lipoproteins in chronic kidney disease: from bench to bedside","volume":"42","author":"Speer","year":"2021","journal-title":"Eur Heart J"},{"issue":"S1","key":"10.1016\/j.atherosclerosis.2025.120563_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-016-1363-8","article-title":"Mineral metabolism and cardiovascular disease in CKD","volume":"21","author":"Fujii","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.nefro.2020.04.020","article-title":"Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease","volume":"40","author":"Quiroga","year":"2020","journal-title":"Nefrol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib24","article-title":"Association of dyslipidemia with renal outcomes in chronic kidney disease","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120563_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/toxins10060237","article-title":"Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in Chronic Kidney Disease (CKD)","volume":"10","author":"Vanholder","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib27","volume":"vol. 13","author":"Fernandez-Prado","year":"2020"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/ndt\/gft080","article-title":"Uraemic dyslipidaemia revisited: role of high-density lipoprotein","volume":"28","author":"Speer","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1194\/jlr.M055624","article-title":"Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease","volume":"56","author":"Reis","year":"2015","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7520231","article-title":"Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease","volume":"2016","author":"Dro\u017cd\u017c","year":"2016","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib31","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","article-title":"Oxidative stress is progressively enhanced with advancing stages of CKD","volume":"48","author":"Dounousi","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-025-01290-2","article-title":"Managing dyslipidemia in chronic kidney disease: implications for cardiovascular and renal risk","volume":"27","author":"Theofilis","year":"2025","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib33","doi-asserted-by":"crossref","DOI":"10.2174\/0115733998259273231101052549","article-title":"Lipids: a major culprit in diabetic nephropathy","volume":"20","author":"Beniwal","year":"2024","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib34","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","article-title":"Lipoprotein metabolism and lipid management in chronic kidney disease","volume":"18","author":"Kwan","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12944-020-01293-9","article-title":"Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study","volume":"19","author":"Katzmann","year":"2020","journal-title":"Lipids Health Dis"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4093\/dmj.2023.0067","article-title":"Dyslipidemia in patients with chronic kidney disease: an updated overview","volume":"47","author":"Suh","year":"2023","journal-title":"Diabetes Metab J"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/ijms21020601","article-title":"The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease","volume":"21","author":"Rysz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib38","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14728222.2017.1369961","article-title":"New perspectives on CKD-induced dyslipidemia","volume":"21","author":"Berm\u00fadez-L\u00f3pez","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib39","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.jrn.2010.05.010","article-title":"Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease","volume":"20","author":"Vaziri","year":"2010","journal-title":"J Ren Nutr"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12944-017-0594-3","article-title":"The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk","volume":"16","author":"Femlak","year":"2017","journal-title":"Lipids Health Dis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120563_bib41","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1681\/ASN.2013111212","article-title":"HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype","volume":"25","author":"Shroff","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9343(93)90144-E","article-title":"Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B","volume":"94","author":"Chait","year":"1993","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib44","series-title":"The persistent underrepresentation of patients with chronic kidney disease in cardiovascular trials: a systematic review and evidence map of exclusion and outcomes","author":"Colombijn","year":"2023"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib45","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","year":"2010","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD\u2014To treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/qjmed\/hcx040","article-title":"Meta-analysis of statins in chronic kidney disease: who benefits?","volume":"110","author":"Messow","year":"2017","journal-title":"QJM An Int J Med"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","year":"2016","journal-title":"Lancet Diabetes Endocrinol [Internet]"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.119042","article-title":"The role of maintaining lower LDL-C level during statin treatment for advanced CKD patients","volume":"399","author":"Yen","year":"2024","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2025.120563_bib50","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/MOP.0000000000000848","article-title":"Inherited conditions resulting in nephrolithiasis","volume":"32","author":"Hoppe","year":"2020","journal-title":"Curr Opin Pediatr"},{"issue":"8934","key":"10.1016\/j.atherosclerosis.2025.120563_bib53","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.12620921","article-title":"Association of Serum phosphate with efficacy of Statin therapy in hemodialysis patients","volume":"17","author":"Massy","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2025.120563_bib55","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long\u2010term Cardiac outcomes in renal transplant recipients receiving Fluvastatin: the ALERT extension Study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ndt\/gfy151","article-title":"Metabolic risk profile in kidney transplant candidates and recipients","volume":"34","author":"Piotti","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s12944-024-02276-w","article-title":"Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis","volume":"23","author":"Bellos","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"10059","key":"10.1016\/j.atherosclerosis.2025.120563_bib58","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4963","article-title":"Statins evidence: when answers also raise questions","author":"Krumholz","year":"2016","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2025.120563_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120563_bib61","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for Lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2025.120563_bib62","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2025.120563_bib63","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.120563_bib64","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cpdd.650","article-title":"Influence of renal function on evolocumab exposure, pharmacodynamics, and safety","volume":"8","author":"Lee","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100483","article-title":"Alirocumab and lipid levels, inflammatory biomarkers, metabolomics, and safety in patients receiving maintenance dialysis: the ALIrocumab in DIALysis study (A phase 3 trial to evaluate the efficacy and safety of biweekly alirocumab in patients on a stable","volume":"4","author":"East","year":"2022","journal-title":"Kidney Med"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2025.120563_bib67","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib68","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","article-title":"Renal drug transporters and drug interactions","volume":"56","author":"Ivanyuk","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2025.120563_bib69","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"issue":"9500","key":"10.1016\/j.atherosclerosis.2025.120563_bib70","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib71","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ekir.2018.09.006","article-title":"Associations of fenofibrate therapy with incidence and progression of CKD in patients with type 2 diabetes","volume":"4","author":"Frazier","year":"2019","journal-title":"Kidney Int Reports"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2025.120563_bib73","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.117556","article-title":"Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial","volume":"393","author":"Doi","year":"2024","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib75","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/jcm11030768","article-title":"The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies","volume":"11","author":"Hadjivasilis","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib76","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1111\/dom.15815","article-title":"Fenofibrate and risk of end\u2010stage renal disease: a nationwide cohort study","volume":"26","author":"Hyun","year":"2024","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111612","article-title":"Not enough known about fenofibrate's kidney effects in people with type 2 diabetes","volume":"210","author":"Jenkins","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ahj.2021.01.018","article-title":"Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)","volume":"235","author":"Ambrosy","year":"2021","journal-title":"Am Heart J"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2025.120563_bib80","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: reduce-it renal","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2025.120563_bib81","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.atherosclerosis.2025.120563_bib82","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib83","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets","volume":"27","author":"Matsushita","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120563_bib85","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1253\/circj.CJ-19-0320","article-title":"Novel \u201cPredictor Patch\u201d method for adding predictors using estimates from outside datasets \u2015 A proof-of-concept study adding kidney measures to cardiovascular mortality prediction","volume":"83","author":"Matsushita","year":"2019","journal-title":"Circ J"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120563_bib86","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s11886-022-01790-6","article-title":"New way to \u201cSCORE\u201d risk: updates on the ESC scoring system and incorporation into ESC cardiovascular prevention guidelines","volume":"24","author":"Graham","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/eurjpc\/zwac176","article-title":"Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP","volume":"30","author":"Matsushita","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib88","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120563_bib89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1053\/j.ajkd.2014.03.013","article-title":"Impact of age on the association between CKD and the risk of future coronary events","volume":"64","author":"Tonelli","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120563_bib90","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2025.120563_bib91","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.atherosclerosis.2025.120563_bib92","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2023-12-3","article-title":"Inclisiran for the treatment of hypercholesterolaemia","volume":"13","author":"Marrs","year":"2024","journal-title":"Drugs Context"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120563_bib94","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib95","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-Cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib96","first-page":"486","article-title":"Lipoprotein(a) and cardiovascular disease: From basic biology to precision medicine","volume":"20","author":"Lamina","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"27","key":"10.1016\/j.atherosclerosis.2025.120563_bib97","first-page":"2360","article-title":"Targeting lipoprotein(a): The next breakthrough in atherosclerotic cardiovascular disease prevention","volume":"44","author":"Tsimikas","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib98","article-title":"Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population","volume":"3","author":"Shiyovich","year":"2023","journal-title":"Eur Hear J Open"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120563_bib99","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of olpasiran on lipoprotein(a) lowering","volume":"84","author":"O'Donoghue","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.atherosclerosis.2025.120563_bib100","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a)","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2025.120563_bib101","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2024.4504","article-title":"Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting Lipoprotein(a)","volume":"331","author":"Nissen","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2025.120563_bib103","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of Lipoprotein(a) formation","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2025.120563_bib104","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":"Increased high-density lipoprotein levels caused by a common Cholesteryl-Ester transfer protein gene mutation","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCRESAHA.117.311145","article-title":"Protein-Truncating variants at the Cholesteryl Ester Transfer protein gene and risk for coronary heart disease","volume":"121","author":"Nomura","year":"2017","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib106","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib\u2014The rebirth of CETP inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib107","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib108","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib109","series-title":"Placebo controlled, double blind, randomized cardiovascular outcome Study to evaluate the effect of 10 mg obicetrapib in participants with ASCVD not adequately controlled despite maximally tolerated lipid modifying therapies","year":"2021"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120563_bib110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2025.120563_bib111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2025.120563_bib112","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2025.120563_bib113","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"301","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib114","article-title":"A single-ascending and repeat-dose study to evaluate the safety, tolerability","year":"2020","journal-title":"Pharmacokinetics, and Pharmacodynamics of LY3561774 [Internet]"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-022-00986-z","article-title":"Treating cardiovascular disease with liver genome engineering","volume":"24","author":"Hurley","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120563_bib116","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib117","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13578-023-01036-0","article-title":"Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice","volume":"13","author":"Zuo","year":"2023","journal-title":"Cell Biosci"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib118","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","article-title":"Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly","volume":"44","author":"Hussain","year":"2003","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib119","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/eurjpc\/zwab229","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the Pan-European retrospective observational study","volume":"29","author":"D'Erasmo","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2025.120563_bib120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long\u2010term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib121","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40256-013-0030-7","article-title":"Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia","volume":"13","author":"Perry","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.atherosclerosis.2025.120563_bib122","series-title":"Community register of medicinal products: lomitapide","year":"2013"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120563_bib123","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-Function mutations in APOC3, triglycerides, and coronary disease","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120563_bib124","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2025.120563_bib125","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2025.120563_bib126","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120563_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.04.098","article-title":"\u2020Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results","volume":"18","author":"Vasas","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2025.120563_bib128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025014613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:30:22Z","timestamp":1783690222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025014613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":127,"alternative-id":["S0021915025014613"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120563","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid lowering therapies in chronic kidney disease: A call to action","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120563"}}